Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151046 · ClinicalTrials.gov registry record · Phase 2
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
A Phase 2 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT01151046 is a Phase 2 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 118 participants.
The verdict
NCT01151046, a Phase 2 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
Interventions
- DRUG Placebo
- DRUG Exemestane
- DRUG MM-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01151046
The ClinicalTrials.gov registry entry for NCT01151046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01151046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01151046 about?
NCT01151046 is a clinical study titled "Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer". To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
What is the current status of trial NCT01151046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2010-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01151046?
The interventions under investigation include: Placebo (DRUG), Exemestane (DRUG), MM-121 (DRUG).
Who is sponsoring clinical trial NCT01151046?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.